



CM HOSPITALAR S.A.

Publicly-traded joint-stock company
CNPJ/ME No. 12.420.164/0001-57
NIRE 35300486854
CVM Code No. 25682
ISIN "BRVVEOACNOR0"
Ticker "VVEO3"

MATERIAL FACT

CM Hospitalar S.A. ("Company" or "Viveo"), as per CVM Instruction No. 358 of January 3, 2002, hereby informs the public in general that, on August 16th, 2021, the Company, BPL Brazil Holding Company S.À.R.L ("BPL Holding") and Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma", and together with BPL Holding, the "Sellers") entered into a definitive stock purchase agreement under which the Company will purchase from the Sellers the entire capital stock of the holding companies BPL Brasil Participações Ltda. and Cannes RJ Participações S.A., which, on their turn, directly or indirectly hold the entire capital stock of Profarma Specialty S.A., Arp Med S.A., Amostra Medicamentos Hospitalares Ltda., Arp Med Ltda. and Íntegra Medical Consultoria S.A. (all together, the "Profarma Specialty") (the "PFS Transaction").

Profarma Specialty was founded in 2014 and offers integrated solutions in the distribution, specialty pharmacy and patient support services. Profarma Specialty has five distribution centers ("DCs") across the country and four specialty pharmacies focused on delivery.

The acquisition of Profarma Specialty will further accelerate the Company's development into an integrated ecosystem of products and services capable of greatly contributing to the improvement of the Brazilian healthcare industry through a more efficient, sustainable supply chain to all stakeholders, from manufactures to final users.

The PFS Transaction does not include AmerisourceBergen Corporation's equity stake in Profarma Distribuidora de Produtos Farmacêuticos S.A.

Also, on this date, the Company signed a stock purchase agreement with CM Medicamentos Especiais LTDA; CM Campinas Medicamentos Especiais LTDA. and CMI Hospitalar LTDA., (all together "Cirúrgica Mafra") to acquire 100% of Cirúrgica Mafra ("CM Acquisition" and together with the PFS Transaction, the "Transactions").

Cirúrgica Mafra has four physical stores and two DCs with more than 12 thousand SKUs in its portfolio. It sells clinical-hospital materials, special medications, nutrition, orthopedic products, compression stocks, infant and geriatric diapers, dermo cosmetics, among other products.

The CM Acquisition will strengthen Viveo's direct to patient strategy and become an important reinforcement to the Patient Support Programs (PSP) ongoing or under development by the Company.

The Transactions will require investments by the Company of approximately R\$ 900 million and the acquired companies generate a combined annual net revenue of approximately R\$ 1.8 billion.

The conclusion of each of the Transactions is subject to certain usual conditions precedent, including (i) the approval of the Brazilian Antitrust Authority (CADE), and, in case of the PFS Transaction, (ii) the approval by the Company's General Meeting for purposes of Article 256 of Law 6,404/76, provided that the Company's controlling shareholders, namely Genoma VI Fundo de Investimento em Participações Multiestratégia and Fundo de Investimentos em Participações Multiestratégia Genoma I, have already formally and definitively agreed to attend such general meeting and vote in favor of the approval of the PFS Transaction.

Ribeirão Preto, August 16th, 2021

Leonardo Almeida Byrro
Chief Executive and Investor Relations Officer
CM HOSPITALAR S.A.